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Abbreviations
D *,7,8-dehydro-9,10-desacetyldoxorubicinone; D ox, doxorubicin; D n r, daunorubicin; P ra,
pirarubicin; IC5 0, inhibitory concentration, the drug concentration required to inhibit 50% of cell
growth; S, doxorubicin-sensitive K562 cells; R, doxorubicin-resistant K562 cells; C D,circular
dichrdism
Abstract
The influence of some metal ions on the degradation of anthracyclines was examined. One of the
degradation products is the 7,8-dehydro-9,10-desacetyldoxorubicinone, D* (), usually formed by
hydrolysis at slightly basic pH. D* is a lipophilic compound with no cytostatic properties. Its formation
could be responsible for the lack of antitumor activity of the parent compound. The coordination of
metal ions to anthracycline derivatives is required to have degradation products. Cations such as
Na+, K+, or Ca2+ do not induce the D* formation however metals which can form stable.complexes
with doxorubicin afford D*. Iron(Ill) and copper(ll) form appreciable amount of D* at slightly acidic pH.
Terbium(Ill) forms D* but its complex is stable only at slightly basic pH. Palladium(ll) which does not
form D*. The influence of the coordination mode of metal ions to anthracycline on the D* formation
is discussed.
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Introduction
Degradation of antitumor compounds is a common problem for pharmacologists. 1 The efficacy of an
antitumor drug is related to the intracellular drug concentration as well as to the rate of cell uptake.2
Anthracycline antibiotics, Doxorubicin (I) and Daunorubicin (l’)(Chart 1) are benzanthraquinone
drugs, which are useful in the treatement of several type of human malignancies.3 Anthracycline are
known to bind different metal cations and to form several complexes with, usually, high stability
constants.4 0 OH 0
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Complexation of these biological active molecules with metal ions has been examined in order i) to
reduce the toxic effects such as dose-dependent cardiotoxicity;5 ii) to improve the antitumor
properties:6 iii) to reproduce some in vivo mechanisms.7
In order to determine the relationships between intracellular drug concentration and the cytotoxic
activity (as well as the degree of resistance) we were interested in the anthracycline degradation in
cell culture.
One of the degradation products of anthracycline, namely 7,8-dehydro-9,10-desacetyl-
doxorubicinone, D* (ll)(Charl; 2), has been idemified8’9 however its biological effects have been
neglected by pharmacologists. In a previous report we have shown that this derivative, which is
detected in cells following incubation with doxorubicin, is formed in the culture medium. 1 0
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We also detected the presence of D* when studying the interactions of cells with the iron
complexes of doxorubicin and pirarubicin; in this case the degradation product is not formed in the
medium but it is already present in the metal complex solution. 1 1 These outcomes prompted us to
further investigate whether other metal ions can form D* giving us the opportunity to discuss about
the chemical requirements necessary to have D* formation.
Results
The metal complexes of anthracycline were prepared following the published procedures12-15
and dissociated by adding hydrochloric acid (0.2 M). The dissociation step usually required less
than one hour except for the Pd(ll) complexes. We verified that the strongly acidic pH (pH<l) was
not responsible of the degradation of anthracyclines. Control experiments were done with the free
anthracycline and D* was not formed in the experimental conditions employed without metal ion.
Iron(lll)-anthracycline systems
Iron(Ill) forms with doxorubicin (and pirar’ubicin) a complex in which three anthracycline are bound to
the metal ion following an octahedral arrangement, [Fe(Dox)3] (111) and [Fe(Pra)3] (I V). 6 Magnetic
susceptibility measurements indicate that the complexes thus obtained are in high spin-form
suggesting that six oxygens are bound to the iron. 2 The anthracyclines act as bidentate ligands
through the C12-carbonyi and the C11-phenolate oxygens forming a six membered chelate ring. 7
Usually the iron complexes are prepared starting from iron(ll), in the form of Mohr’s salt as source of
iron(Ill), following air-oxidation to iron(Ill). This method is generally considered the best way to
prepare these complexes and to avoid formation of iron hydroxides. 8 The metal ion can be added
either to an anthracycline buffer solution at pH 7 (method i) or to an unbuffered solution and the
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subsequent addition of the stoichiometric amount of NaOH necessary to deprotonate once the
anthracycline (ii). Both reactions are very fast and depending on the procedures used, two different
CD spectra were obtained. In buffer solution (method i) and also in the presence of an excess of
iron, the CD spectrum is prevalently characterized by a strong positive band centred at 630 nm (Fig.
1)" this band is typical of the iron complexes of daunorubicin derivatives 2,19 and characterizes
what will be hereafter labelled a D-type spectrum. 24 hours later, after dissociation of the complex,
we detected the presence of D* in an amount ranging from 0 to 10% of the initial anthracycline
concentration.
If the metal complexes are prepared in water with the subsequent addition of NaOH, 24 hours later
the amount of D* raised to 25-30%: the CD spectrum did not evolve with time and still exhibited two
positive bands at 500 and 605 nm, characteristics of an A-type spectrum (Fig. 1).1 2 The cytostatic
properties of the A-type complex are drastically reduced, particularly in the case of doxorubicin-
resistant cells (IC50 [R]=3000 nM compared to 200 nM for Dox).
A: [Dox]
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Figure 1. CD spectra of the 1:3 Fe(lll)/Dox complex, in the A-type and in the D-type forms.
Experimental conditions" [Dox]= 5x10-4 M; [KCI] 0.01 M; pH 6.0.
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This complex is formed in water at pH around 5-6; at these values the hydrolytic pathway to get D* is
discouragead.8 In fact in the same conditions, free doxorubicin did not yield D*.
Copper(ll)-doxorubicin systems
Copper(ll) is known to form with doxorubicin two complexes depending on the pH and on the
stoichiometric ratio. 2,20 At pH 6.5 a first complex is formed: two anthracyclines are bound to the
metal ion through the oxygens of one phenolate and one carbonyi functions, [Cu(Dox)2] (V), with
no particularly preference for one position.21 At pH higher then 7,. the prevalent species is a 1"1
complex, probably with a polymeric structure, [Cu-Dox]n (V I). The two complexes were prepared as
described13 and their spectroscopic properties were checked. The dissociation of the two
complexes was very fast: in less than 30 minutes an orange solution was recovered indicating the
presence of free doxorubicin. Two hours after their preparation, we checked the cytostatic
properties as well as the doxorubicin degradation of the complex V. We found the same IC50 (4 nM
for [S] cells) that for the free drug and no detectable D*. 24 hours later we checked again: the metal
complex was inefficient against tumour cells at the same concentration of free doxorubicin
(IC50[S]>10nM) and an amount of D* ranging from 8 to 10% was detected, with no difference in the
experimental conditions used.
Terbium(lll).-anthracy..cline systems
At pH 7.2 terbium(ill) binds two molecules of anthracycline, formina [Tb(Dox)2] (VII).22 The
coordination has been established also by NMR spectra to occur through the oxygens at C11 and
C12.1 4,23 The CD spectrum of complex VII exhibits positive bands at 490, 530 and 560 nm and
one negative at 595 nm (Fig. 2).
Dissociation of VII was very fast and all the initial doxorubicin was recovered (IC50[S]=5.5 nM). This
complex evolved with time: after three weeks the new CD spectrum exhibited positive bands at 540
and 570 nm. We can accelerate the formation of this second species, VIII, raising the reactionnel
pH to 8. In these conditions only three days are required. The dissociation of VIII was very slow and
we recovered only the 50% of the initial amount of doxorubicin, the remainder being degraded to
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Figure 2. CD spectra of the 1:2 Tb(lll)/Dox complex, after 2 hour (pH 7.2) and after 3 days (pH 8).
Experimental conditions: [Dox] lx10-4 M; [KCI]- 0.01 M
Palladium(ll)-doxorubicin.. systems
Palladium(ll) reacts very slowly with doxorubicin; the reaction can take place only in slightly acidic
pH.15 Palladium(ll) forms with the doxorubicin two complexes. In the first one, IX. two drug
molecules are bound to one metal ion forming [Pd(Dox)2] whereas the formation of the second
species, X, occurs to a 1:1 molar ratio of Pd(ll) per doxorubicin. Coordination of palladium(ll) to the
anthracycline would occur at the C12-carbonyl and the C11-phenolate oxygens and to the amino
group of daunosamine.24 In particularly in the complex IX, one doxorubicin is bound through the
oxygens at Cll and C12 and a second one by the NH2 group. The complex X, [Pd-Dox]2, is a
dimer where the two coordinative positions still free in IX are occupied by another Pd(ll) ion. The
coordination to the amino group has been confirmed also by NMR spectra.25
As palladium(ll)is inert, dissociation of IX and X required more time (24 hours) and stronger
conditions (1.2 M HCI) than all other complexes tested. We checked the cytostatic properties of the
two complexes: we found that the complexation to Pd(ll) ions (IC50[R]=290 nM) did not modify the
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inhibitory effect on the cell proliferation of free doxorubicin (IC50[R]= 200 nM) and no D* was
detected.
Discussion
The instability of anthracycline derivatives in aqueous solution and in cell culture media has been
recognised by several investigators.
Among them Beijnen eta/.8,9,26 have identified the anthracycline degradation products formed in
acidic media (pH<4) or slightly basic pH media (pH~8). They showed that degradation of
doxorubicin at pH higher than 7 yielded mainly a pink coloured aglycone in which full aromatization
of the ring A occurred. This compound, identified as D*, can be also formed at strongly acidic pH
(pH<1)27 and by photodegradation.28 Structural analogies of the doxorubicin with corticosteroids,
i.e. hydrocortisone, suggested a possible mechanism of the D* formation at basic pH.8
Corticosteroids possess a C17 (-ketol side chain29 analogue to the C9 (-ketol substituent in
doxorubicin which could constitute an extra protonation site. Reversible enolization and ionization
of this function should be possible at basic pH: the determination of the corresponding pKa would
be hampered by overlap with the deprotonation of the phenolic group. In analogy with the
degradation of corticosteroids, the enolization step is assumed to be the first step of the
degradation reaction of doxorubicin. The enolate anion arising from keto/enol tautomerization and
deprotonation may be involved in a tautomeric equilibrium with its 13-o1-14-aidehyde derivative. A
concertated mechanism entraining the cleavage of the C9 side chain and the aminosugar moiety
yields D*. The high stability of the resulting degradation product is the driving force of the full
aromatization of the A ring after cleavage of the C9 side chain.
D*, a lipophilic compound, enters in cells very rapidly but unfortunately it has no cytostatic
properties:l I its formation could explain the reduced antiproliferative activity observed in the case
of degradated anthracycline. 1 0
An influence of metal ions on the D* degradation was already proposed26 but not verified. In the
case of the Tb(lll)complexes, the slightly basic pH at which this complex is formed could be
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considered as responsible of the doxorubicin degradation. It has to be observed that at the same
pH value, free doxorubicin is more degrated (50% in 1 day) than if complexed to terbium(Ill) ions. It
means that in this case the metal ion seems to have a protecting role against the D* formation.
However from our results the formation of D* seems to be related to the different coordination
mode of the metal ions. In fact coordination at the C5-C6 site, which has been established for
Cu(ll)21 and Tb(lll)14 seems to prevent D* formation more than the coordination at the Cll-C12
site. The anomalous case of terbium(Ill) has been related to the high value of the reactionnel pH.
The C11-C12 position has probably a positive effect on the enol formation, first step of the
degradation pathway.
In addition under slightly basic conditions the rate of the glycosidic bond cleavage is strongly
dependent on the electronic structure of the aglycone part8 while at acidic pH the structural
modifications in the sugar moiety are more important.26
Palladium(ll) is coordinated to doxorubicin also by the amino group of the daunosamine and, in this
case D* has been never observed.
This important difference in the coordination mode of metal ion seems to play a role in D* formation.
This fact could be related to the cleavage of the glycosidic bond which is a crucial step in the
concertated mechanism yielding the D* formation.
From a recent paper31 we can suggest a possible explanation for the D* formation in the iron
complexes. Reexamining the structure of [Fe(Dnr)3] by EPR, EXAFS, and MSssbauer techniques,
Matzanke et al. observed that at the 1:3 [Fe]/[Dnr] ratio the complex exists only in a polymeric form.
To justify the anisotropy of this complex two "speculative" models of polymer were proposed: in the
first one [Fe(Dnr)3] octahedra are attached to each other by Dnr-Dnr stacking forming a three
dimensional polymeric structure. In the second case a linear polymer would be composed of planes
of two Dnr molecules binding Fe(lll) ions with the oxygens at Cll and C12. The axial positions
would be occupied by OH groups bridging two planes. Planes of Dnr dimers would be randomly
distributed in the linear polymer with in both cases the amino group of the daunorubicin involved in
the stacking of the anthracyclines.
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Making the hypothesis that the structure of the [Fe(Dox)3] complex exhibiting a D-type CD
spectrum is similar to that of the [Fe(Dnr)3] we can suggest that the involvment of the amino group
in the Dox stacking prevent D* formatio as it was observed in the case of the palladium complex.
Obviously these hypothesis require to be verified by the analysis of other complexes of
anthracycline, which are actually under study.
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